Joint-Stock Company (S.A.)
Polpharma Biologics
Polpharma Biologics Spółka Akcyjna
Joint-Stock Company (S.A.)
Polpharma Biologics Spółka Akcyjna
Polpharma Biologics Spółka Akcyjna (KRS 0000763945, NIP 9571112470) is a Polish company, headquartered in Gdańsk, Pomorskie voivodeship. Polpharma Biologics operates in: Scientific research and development (PKD 72.10.Z). Industry: Research and development. The company has been listed in the National Court Register since December 31, 2018. Polpharma Biologics's most recently reported net revenue was 66.8 M PLN for 2021.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Other activities
WWW.POLPHARMABIOLOGICS.COMCredibility rating
36.8 / 100
Poor credibility
Insolvency risk
Low
Elevated threat
Closure risk
30
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Spółka wykazuje sygnały niestabilności organizacyjnej: częste zmiany w zarządzie. Może to wskazywać na podwyższone ryzyko współpracy.
Shareholder changes
0
0/8 yrs
Board changes
10
10/8 yrs
PKD changes
2
2/8 yrs
Name changes
0
0/8 yrs
Data from 8 years of registry activity.
Payment reliability score from 2019–2021
Current: E (37/100)
Trend: deteriorating (-5.6 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Standard limit from 2019–2021
Current: 9.5 M PLN
Safe: 1.9 M PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Founded
December 31, 2018
7 years in operation
Legal form
Joint-Stock Company (S.A.)
Registry: RejP
Headquarters
GDAŃSK
POMORSKIE
Primary PKD
72.10.Z
Scientific research and development
Share capital
1.8 B PLN
Shareholders
1
shareholder
Board
5 people
Sup. board: 3
Filed years
3 years
2019–2021 · profitable: 0/3
Registry entries
61
latest: July 31, 2026
Risk signals
Revenue
66.8 M PLN
2021
Net profit
-389.2 M PLN
2021
Assets
476.4 M PLN
2021
Equity
270.8 M PLN
2021
EBITDA
N/A
2021
no depreciation data
Valuation
92.4 M PLN
Low confidence
Low confidence
People holding roles at Polpharma Biologics according to the Polish National Court Register. Follow a name for that person's full profile and their other companies.
Rate business credibility - Polpharma Biologics.
No ratings
Consumer brands owned by this company.
Umbrella brand
Spółka biotechnologiczna grupy Polpharma — leki biopodobne, produkcja kontraktowa.
Visit website
Umbrella brand
Największa polska firma farmaceutyczna — leki recepturowe i OTC; marka grupy.
Visit website
News
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
Answers to questions about the company's activity, registered office, identifiers, financial data, capital and control.
Polpharma Biologics has 1 shareholder.
Yes - Polpharma Biologics's majority owner is POLPHARMA BIOLOGICS GROUP B.V..
Polpharma Biologics's board has 5 members.
Latest reporting year
2025
Available years
7
Filing entries
0
20 historical registry entries for Polpharma Biologics
Share capital change, Articles of association amended, Change in Section 1 (basic data)
GD.VII NS-REJ.KRS/25620/25/634
Board change
GD.VII NS-REJ.KRS/26/26/68
Board change
GD.VII NS-REJ.KRS/3187/26/709
Articles of association amended, Secondary PKD code change
GD.VII NS-REJ.KRS/9652/26/672
Filing documents submitted (4 documents)
Competing companies or those operating in the same market segment as Polpharma Biologics (industry: Research and development).
WARSZAWA· Research and development
Revenue 2025: 126.1 M PLN
GDYNIA· Research and development
Revenue 2024: 117.1 M PLN
WARSZAWA· Research and development
Revenue 2025: 98.4 M PLN
WARSZAWA· Research and development
Revenue 2024: 86.1 M PLN
WARSZAWA· Research and development
Revenue 2024: 74.2 M PLN
KRAKÓW· Research and development
Revenue 2024: 59.9 M PLN
